20.47
+7.17%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Cryoport
From its filings with the US Securities and Exchange Commission
Cryoport is based in Brentwood, Tennessee and is incorporated in Nevada. Its shares trade on Nasdaq under the ticker CYRX. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $176.2m and net income of $78.3m. At that date it held total assets of $765.0m and shareholders' equity of $502.6m.
We are a leading global provider of integrated, temperature-controlled supply chain solutions for the life sciences, with a strong focus on supporting the rapidly growing cell and gene therapy (“CGT”) market. Our solutions are purpose-built to support a broad range of global life sciences markets, including biopharmaceutical and pharmaceutical companies, the animal health markets, reproductive medicine, academic institutions, research, and government agencies. Our solutions help our customers ensure the safe, compliant storage, handling, and delivery of high value, temperature sensitive biological materials, including cell and gene therapies and immunotherapies.
We place particular emphasis on the CGT market, our fastest growing market, by delivering highly specialized, end-to-end supply chain solutions that support cell and gene therapy programs from preclinical research, through clinical trials, and ultimately to the global commercialization of approved therapies. As of December 31, 2025, Cryoport supported 760 clinical trials, and 20 commercially approved cell and gene therapies.
Our integrated temperature-controlled supply chain solutions combine advanced logistics, biostorage, kitting and labelling, clinical sample management, collection and cryopreservation services for cell therapies starting materials, cryogenic systems manufacturing, and an industry-leading informatics platform that integrates all our solutions.
Quoted from its 10-K, filed 5 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Health Care Equipment & Supplies
- Listed since
- 24 Jul 2015
- Employees
- 684
- Website
- cryoport.com ↗
- Head office
- 112 WESTWOOD PLACE, SUITE 350, BRENTWOOD, TN, 37027
- Incorporated in
- NV
- Classification
- Pharmaceutical Preparations
- Filer status
- Accelerated filer
Leadership
Pay as last reported
- Mr. Jerrell SheltonChairman of the Board, President, Chief Executive Officer, since 2012$1.9m
- Mr. Robert StefanovichChief Financial Officer, Senior Vice President, Chief Administrative Officer$966,897
- Mr. Edward ZecchiniSenior Vice President, Chief Digital and Technology Officer, since 2013$1.0m
- Mr. Mark SawickiSenior Vice President, Chief Scientific Officer$930,768
- Mr. Richard BermanLead Independent Director$439,988
- Ms. Linda BaddourIndependent Director$402,488
- Mr. Daniel HancockIndependent Director$394,988
- Dr. Robert HaririIndependent Director$418,988
- Mr. Ram JagannathIndependent Director$70,000
- Dr. Ramkumar MandalamIndependent Director$410,604
- Mr. Scott EcksteinInvestor Relations, since 2022
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 48
- Environment
- 37
- Social
- 49
- Governance
- 56
- Direct emissions (scope 1)
- 1,352 t
- Energy emissions (scope 2)
- 4,879 t
- Value chain emissions (scope 3)
- 10,022 t
- Women in the workforce
- 31%
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Cryoport Inc boasts a strong and established reputation as a leading provider of temperature-controlled logistics solutions for the life sciences industry. With their specialized expertise in cryogenic shipping, Cryoport has developed a highly advanced and reliable technology platform to safeguard the transport of sensitive biologics, pharmaceuticals, and other life-saving materials. This technological prowess has allowed Cryoport to secure numerous high-profile partnerships with top companies in the healthcare and biotech sectors, solidifying their dominant position in the market.
- Furthermore, Cryoport's extensive global network of over 650 locations, including strategic partnerships with major logistics providers, enables them to offer comprehensive end-to-end supply chain solutions, facilitating the efficient and safe delivery of temperature-sensitive products across borders.
Weaknesses
- One notable weakness for Cryoport is the high dependency on the life sciences industry. Any significant downturn or disruption in the industry could have an adverse impact on Cryoport's financial performance. Diversification into other sectors or industries could mitigate this risk and provide a more stable revenue base.
Opportunities
- The rapid growth of the biopharmaceutical industry presents significant opportunities for Cryoport. As the demand for personalized medicine and cell-based therapies continues to rise, the need for specialized cryogenic shipping solutions will increase accordingly. Cryoport can leverage its existing technology and expertise to capture a larger share of this expanding market and form new strategic alliances to further enhance their presence.
- Additionally, Cryoport has the potential to expand its offerings beyond temperature-controlled logistics. They can explore partnerships or acquisitions in related fields such as cold chain packaging or supply chain analytics, further diversifying their revenue streams and strengthening their position as a comprehensive solution provider.
Threats
- Increased competition in the temperature-controlled logistics space poses a threat to Cryoport. As the industry continues to grow, new players may enter the market, offering similar or improved services. Cryoport must proactively invest in research and development to stay at the forefront of technological advancements and maintain their competitive edge.
- Additionally, regulatory changes or stricter compliance requirements in the transportation of temperature-sensitive materials may pose challenges. Cryoport must stay updated with evolving regulations and ensure their operations comply with quality standards and guidelines set by regulatory bodies, both domestically and internationally.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.